The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 ...

Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer.

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The 2025 meeting of the American Society of Hematology features some of the newest developments in blood cancers and rare ...

Perettie’s confidence stems from data shared at ASH on Dec. 6, when Kite revealed that patients treated with the Arcellx-partnered autologous therapy achieved a 96% overall response rate at the 15.9 ...

Gilead is hoping to break ground early next year on its Chess Hatch campus as part of its plans to expand its presence in ...